89 related articles for article (PubMed ID: 15110847)
1. Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists.
Ohnmacht CJ; Albert JS; Bernstein PR; Rumsey WL; Masek BB; Dembofsky BT; Koether GM; Andisik DW; Aharony D
Bioorg Med Chem; 2004 May; 12(10):2653-69. PubMed ID: 15110847
[TBL] [Abstract][Full Text] [Related]
2. 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist.
Seto S; Tanioka A; Ikeda M; Izawa S
Bioorg Med Chem Lett; 2005 Mar; 15(5):1485-8. PubMed ID: 15713412
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists.
Seto S; Tanioka A; Ikeda M; Izawa S
Bioorg Med Chem; 2005 Oct; 13(20):5717-32. PubMed ID: 15993086
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists.
Seto S; Tanioka A; Ikeda M; Izawa S
Bioorg Med Chem Lett; 2005 Mar; 15(5):1479-84. PubMed ID: 15713411
[TBL] [Abstract][Full Text] [Related]
5. Analysis of crucial structural requirements of 2-substituted pyrimido[4,5-b][1,5]oxazocines as NK(1) receptor antagonist by axially chiral derivatives.
Seto S; Asano J
Bioorg Med Chem; 2007 Aug; 15(15):5083-9. PubMed ID: 17540575
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of dibenz[b,f][1,5]oxazocine derivatives for agonist activity at κ-opioid receptor.
Mitra S; Banerjee TS; Hota SK; Bhattacharya D; Das S; Chattopadhyay P
Eur J Med Chem; 2011 May; 46(5):1713-20. PubMed ID: 21392859
[TBL] [Abstract][Full Text] [Related]
7. Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
Shue HJ; Chen X; Schwerdt JH; Paliwal S; Blythin DJ; Lin L; Gu D; Wang C; Reichard GA; Wang H; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Nomeir AA; Morgan CA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2006 Feb; 16(4):1065-9. PubMed ID: 16290143
[TBL] [Abstract][Full Text] [Related]
8. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.
Ikeura Y; Ishichi Y; Tanaka T; Fujishima A; Murabayashi M; Kawada M; Ishimaru T; Kamo I; Doi T; Natsugari H
J Med Chem; 1998 Oct; 41(22):4232-9. PubMed ID: 9784098
[TBL] [Abstract][Full Text] [Related]
9. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
[TBL] [Abstract][Full Text] [Related]
10. Cyclic urea derivatives as potent NK1 selective antagonists.
Shue HJ; Chen X; Shih NY; Blythin DJ; Paliwal S; Lin L; Gu D; Schwerdt JH; Shah S; Reichard GA; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Liu F; Nomeir AA; Morgan CA; Varty GB
Bioorg Med Chem Lett; 2005 Sep; 15(17):3896-9. PubMed ID: 16019209
[TBL] [Abstract][Full Text] [Related]
11. Cyclobutane derivatives as potent NK1 selective antagonists.
Wrobleski ML; Reichard GA; Paliwal S; Shah S; Tsui HC; Duffy RA; Lachowicz JE; Morgan CA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3859-63. PubMed ID: 16682196
[TBL] [Abstract][Full Text] [Related]
12. Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives.
Hoffmann-Emery F; Hilpert H; Scalone M; Waldmeier P
J Org Chem; 2006 Mar; 71(5):2000-8. PubMed ID: 16496986
[TBL] [Abstract][Full Text] [Related]
13. NK1 antagonists based on seven membered lactam scaffolds.
Elliott JM; Carlson EJ; Chicchi GG; Dirat O; Dominguez M; Gerhard U; Jelley R; Jones AB; Kurtz MM; Tsao Kl; Wheeldon A
Bioorg Med Chem Lett; 2006 Jun; 16(11):2929-32. PubMed ID: 16574413
[TBL] [Abstract][Full Text] [Related]
14. Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
Meurer LC; Finke PE; Owens KA; Tsou NN; Ball RG; Mills SG; Maccoss M; Sadowski S; Cascieri MA; Tsao KL; Chicchi GG; Egger LA; Luell S; Metzger JM; Macintyre DE; Rupniak NM; Williams AR; Hargreaves RJ
Bioorg Med Chem Lett; 2006 Sep; 16(17):4504-11. PubMed ID: 16831551
[TBL] [Abstract][Full Text] [Related]
15. [Conformational analysis of peptide antagonists in the design of pseudopeptide and non-peptide antagonists].
Goldstein S; Neuwels M; Lassoie MA; Houssin R; Caumont K; Differding E; Henichart JP
J Pharm Belg; 1995; 50(2-3):213-22. PubMed ID: 7545749
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis and optimization of NK(1) receptor antagonists through modulation of atropisomer interconversion properties.
Albert JS; Ohnmacht C; Bernstein PR; Rumsey WL; Aharony D; Alelyunas Y; Russell DJ; Potts W; Sherwood SA; Shen L; Dedinas RF; Palmer WE; Russell K
J Med Chem; 2004 Jan; 47(3):519-29. PubMed ID: 14736234
[TBL] [Abstract][Full Text] [Related]
18. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
19. Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
Finke PE; Meurer LC; Levorse DA; Mills SG; Maccoss M; Sadowski S; Cascieri MA; Tsao KL; Chicchi GG; Metzger JM; Macintyre DE
Bioorg Med Chem Lett; 2006 Sep; 16(17):4497-503. PubMed ID: 16824752
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception.
Rittner HL; Lux C; Labuz D; Mousa SA; Schäfer M; Stein C; Brack A
Anesthesiology; 2007 Dec; 107(6):1009-17. PubMed ID: 18043070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
